Market Signal Briefing

THIS PRESS RELEASE MAY NOT BE PUBLISHED, DISTRIBUTED OR TRANSMITTED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN AND SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE OFFER OR SALE OF SECURITIES WOULD CONSTITUTE A VIOLATION OF ANY APPLICABLE LAW.

IXICO PLC (LSE:IXI, OTC:PHYOF), the neuroscience imaging specialist, has won a new contract and extended an existing one worth a combined £1.2 million, strengthening its position in biomarker analytics for neurological disorders.

The AIM-listed company said the new agreement, signed with a major global biopharma client, would support the validation of a diagnostic blood test designed to help detect an undisclosed neurodegenerative disease.

The three-year deal will use IXICO’s artificial intelligence-based platform to analyse data from a prospective blood-based biomarker test, a growing area of interest in drug development because it can help diagnose brain conditions earlier and less invasively than imaging.

Alongside this, IXICO has expanded its work on an Alzheimer’s disease clinical trial, adding a range of new activities over the coming years.

The extension builds on a series of smaller contract increases secured in recent months, which the company said had bolstered its long-term order book.

Bram Goorden, chief executive, said: “The new contract win marks our continued expansion and expertise in the blood-based biomarker field.

"The sustained period of contract extensions culminating in this important Alzheimer’s disease clinical trial demonstrates the demand for IXICO’s services and expertise, the consistent quality of our work, and the value we provide to major biopharma clients.”

The company said the deals reflect continued progress under its “Innovate, Lead, Scale” strategy, aimed at broadening its global reach and deepening relationships with pharmaceutical partners developing treatments for neurological disorders.

The company anticipates higher oil and gas production but warned that earnings in its integrated liquefied natural gas division will be hit by maintenance activity.

Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) reported steady third-quarter production at its Segilola gold mine in Nigeria and reaffirmed its full-year guidance, as it prepares to pay its next quarterly dividend.

For the three months to September 30, the London- and Toronto-listed miner poured 22,617 ounces of gold and sold 19,650 ounces at an average price of US$3,535 an ounce, generating US$69.5 million in revenue.

The company ended the period with nearly 6,000 ounces of unsold bullion and doré (the unrefined alloy produced before final refining), which it said was well positioned to benefit from higher gold prices.

Processing remained strong, with 250,459 tonnes of ore milled at an average grade of 3.11 grammes per tonne and a recovery rate of 94.3%.

Thor kept its full-year production target at 85,000 to 95,000 ounces and its all-in sustaining cost guidance between US$800 and US$1,000 an ounce.

Chief executive Segun Lawson said the miner’s decision to remain unhedged had allowed it to take advantage of record gold prices.

He added that Thor had completed the consolidation of its ownership in the Douta Project in Senegal and strengthened its exploration pipeline with the acquisition of the nearby Bousankhoba licence.

Drilling at Segilola continued to identify high-grade zones below the existing open pit, while exploration in Senegal and Côte d’Ivoire will ramp up following the wet season.

Thor declared a quarterly dividend of C$0.0125 a share, payable on November 14, maintaining the policy introduced earlier this year.

CALGARY, AB / ACCESS Newswire / October 15, 2025 / Valeura Energy Inc. (TSX:VLE)(OTCQX:VLERF) ("Valeura" or the "Company") is pleased to announce that via a wholly-owned subsidiary, and together with its partner, Pinnacle Turkey, Inc. ("Pinnacle"), it has entered into an agreement with a subsidiary of Transatlantic Petroleum LLC ("Transatlantic") to explore for and develop hydrocarbons in the deep rights formations of the Thrace basin of northwest Türkiye (the "Joint Venture"). Dr. Sean Guest, President and CEO commented: "Despite our strategic pivot toward the Asia-Pacific region, we have maintained our conviction that the deep gas play we discovered in northwest Türkiye offers significant potential to add value to the Company.

Vet chain CVS Group (AIM:CVSG) will be in focus oin Wednesday after the Competition and Markets Authority proposed a package of 21 measures aimed at overhauling the market to improve transparency, consumer choice and reduce costs.

The provisional findings of its investigation identified concerns that pet owners often lack information about prices, treatments, and whether their local practice is independently owned or part of a larger corporate group, like CVS.

The CMA also found consumers are paying significantly more for medicines and services than necessary, with average vet prices rising 63% between 2016 and 2023.

Proposals include requiring vet businesses to publish comprehensive price lists, be clear if they are part of a large group, and make sure that their policies and processes allow vets to act in the best interests of pets and pet owners

It proposed capped fees for written prescriptions at £16, automatic written prescriptions for frequently used medicines, and itemised quotes for treatments over £500.

The CMA also recommends a new price comparison website and updates to the regulatory framework, which currently only applies to individual professionals, not businesses.

Martin Coleman, chair of the inquiry group, said: "Pet owners are often left in the dark, not knowing whether their practice is independent or part of a chain or what a fair price looks like.

"They are sometimes committing to expensive treatment without understanding the price in advance. And they do not always feel confident asking for a prescription or buying medicine online - even when it could save them hundreds of pounds."

The CMA said its final decision will be published by March 2026. Some changes could be implemented before the end of that year, with smaller vet businesses allowed more time to comply.

-

Conference brings together customers, partners and industry leaders to exchange ideas, challenge assumptions and build connections that drive the industry forward

AMSTERDAM--(BUSINESS WIRE)--E2open, a WiseTech Global Group company, today kicks off Connect 2025 Global Supply Chain Summit, its flagship customer conference in Amsterdam. For three days, industry leaders, innovators and disruptors from around the world come together to collaborate and shape the future of supply chain innovation.

“We are delighted to host hundreds of customers at this global event to discuss emerging trends, innovative strategies and practical solutions that can help companies navigate today’s rapidly evolving supply chain landscape,” said Mark Hall, CEO of e2open. “Connect reflects how our organization – together with our customers and broad network of enterprises – is reimagining what’s possible for supply chain, logistics, and trade operations worldwide.”

Among the featured speakers at Connect are customers, company leaders, and guest keynote Oliver Kahn, a World Cup and Champions League winner widely regarded as one of football’s greatest goalkeepers, who will share lessons in leadership, resilience and empowering teams to thrive in high-performance environments. In the plenary sessions, three featured customer speakers will detail their digital transformation journeys, technology use cases including applied AI in supply chain, and multi-enterprise collaboration. Their stories cross industries including high-tech, manufacturing, and consumer packaged goods. E2open-led plenary sessions will showcase innovations including agentic AI, the latest product releases, and an interactive exploration of the art of the possible for complex supply chain transformations.

The Connect agenda features over 40 breakout sessions, more than half led by customers representing more than 20 industries across all product areas, and a range of business topics, including AI, compliance, data, risk management and resilience, supply assurance, and visibility. Panel discussions, roundtables and breakout sessions feature several leaders from customer companies, highlighted at connect.e2open.com/speakers. E2open solution experts will host product innovation breakouts, technology demos, and interactive sessions in the Engagement Zone.

Positioned as a barometer for broader supply chain priorities, Connect highlights the industry’s accelerating focus on AI, digital transformation and resilience, making it a timely reflection of where global trade and logistics operations are headed next. In addition to its annual customer and partner awards that will take place at Connect, e2open recognizes Shippeo, Allen Lund Company, Kharon, Accenture, Goikid Consulting and Quantix as sponsoring partners of the conference.

For more information, visit connect.e2open.com.

About e2open

E2open, a WiseTech Global Group company, is the connected supply chain software platform that enables the world’s largest companies to transform the way they make, move and sell goods and services. With the broadest cloud-native global platform purpose-built for modern supply chains, e2open connects more than 500,000 manufacturing, logistics, channel and distribution partners as one multi-enterprise network tracking over 18 billion transactions annually. Our SaaS platform anticipates disruptions and opportunities to help companies improve efficiency, reduce waste and operate sustainably. Moving as one.™ Learn More: www.e2open.com.

E2open and “Moving as one.” are the registered trademarks of E2open, LLC. All other trademarks, registered trademarks and service marks are the property of their respective owners.

More News From E2open

Back to Newsroom

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Molina Healthcare, Inc. ("Molina" or "the Company") (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 5, 2025 and July 23, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before December 2, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Molina withheld adverse information about its "medical cost trend assumptions." The Company suffered from a "dislocation between premium rates and medical cost trend." The Company was likely to cut its financial guidance for fiscal year 2025. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Molina, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Synovus Financial Corp. (NYSE:SNV) will release earnings results for the third quarter, after the closing bell on Wednesday, Oct. 15.

Analysts expect the Columbus, Georgia-based company to report quarterly earnings at $1.35 per share, up from $1.23 per share in the year-ago period. Synovus Financial projects quarterly revenue of $603.18 million, compared to $564.72 million a year earlier, according to data from Benzinga Pro.

On July 24, Pinnacle and Synovus announced an $8.6 billion all-stock merger.

Shares of Synovus Financial gained 3.6% to close at $47.84 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Truist Securities analyst David Smith maintained a Buy rating and cut the price target from $58 to $56 on Sept. 24, 2025. This analyst has an accuracy rate of 71%.
Keefe, Bruyette & Woods analyst Brady Gailey downgraded the stock from Outperform to Market Perform and decreased the price target from $65 to $50 on Aug. 13, 2025. This analyst has an accuracy rate of 75%.
Stephens & Co. analyst Russell Gunther maintained an Equal-Weight rating and cut the price target from $60 to $54 on July 29, 2025. This analyst has an accuracy rate of 67%.
Barclays analyst Jared Shaw maintained an Overweight rating and cut the price target of $70 to $65 on July 28, 2025. This analyst has an accuracy rate of 68%.
DA Davidson analyst Gary Tenner maintained a Buy rating and raised the price target from $60 to $63 on July 18, 2025. This analyst has an accuracy rate of 77%
Considering buying SNV stock? Here’s what analysts think:

Read This Next:

Jim Cramer On FactSet: ‘Holy Cow, It’s Way Too Cheap’ — Also Weighs In On Freeport-McMoRan
Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

SummaryAlexander & Baldwin’s 15% correction offers a value entry, as fundamentals and dividend coverage remain strong despite regional economic softness.Debt metrics are healthy with a 95% fixed-rate structure, ample liquidity, and manageable maturities, reducing refinancing or interest rate risks.Portfolio quality is solid, anchored in resilient tenants and stable occupancy, though Hawaii’s slowdown poses near-term leasing pressure risks.With FFO growth guidance raised ~17% and payout at 56%, dividend sustainability and upside potential justify a speculative buy. Eric Broder Van Dyke/iStock Editorial via Getty Images

When it comes to REITs, I am usually willing to take riskier bets for greater total return prospects in the long run. I size my positions in a way that credit events in

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Mecca Bingo and Grosvenor Casino owner Rank Group PLC (LSE:RNK) said it has started its new financial year strongly and is confident of hitting full-year targets. 

Like-for-like net gaming revenue of £210.2 million was generated in the three months to 30 September, up 9% on the year before.

The performance remains driven by Grosvenor casinos, where revenue rose 8%, and Digital, where underlying revenue growth hit 13%.

Grosvenor grew 10% outside London, compared to 4% in the capital, which was supported by a "significant step up" at the newly refurbished Victoria Casino on Edgware Road.

Gaming machine revenues grew 12%, with the rollout of 471 additional machines across the estate since late August, with a target of 850 machines

Mecca venues saw like-for-like NGR growth of 5%, with customer visits down 1% but spend per visit up 6%.

In Spain, NGR was down 1% due to platform capacity issues, which the company said are being addressed with the launch of a new bingo platform that is expected to return this arm to growth in the second quarter.

Chief executive John O'Reilly said: "We have started the year strongly and are confident of delivering group like-for-like operating profit in line with expectations, notwithstanding the significant cost increases we have incurred in employer national insurance contributions, the national living wage and the new statutory levy."

He said speculation about tax changes in the upcoming Budget is "hanging over the business" but talks with HM Treasury have been held to emphasise the implications how this might affect employment levels and future investment.

"Last year the group generated £44.6 million in profit after tax, having paid HMRC and local authorities £188 million in taxes. The Rank Group, with its strong UK focus, is certainly paying its fair share."

Shares of LVMH popped 12% Wednesday after the French conglomerate posted growth for the first time this year and vowed to solidify its leadership in the global luxury space.

In an update after European trading hours on Tuesday, LVMH — the world's biggest luxury conglomerate and one of Europe's most valuable companies — said revenue for the three months to September came in at 18.3 billion euros ($21.3 billion).

It fell below the 19.1 billion euro revenues scooped up in the third quarter of last year, but beat analysts' expectations.

The Paris-listed firm — whose extensive portfolio of brands includes Louis Vuitton, Tiffany & Co., Christian Dior and Moet & Chandon — is seen as a bellwether for the global luxury goods market.

Currency headwinds, trade tensions and economic disruptions weighed on its performance in the first nine months of the year, the firm said, touting its "resilience and ... powerful innovative momentum" in the third quarter. LVMH's wine and spirits division posted a recovery after growth was dampened by uncertainty around China's new levies on European Union cognac and new U.S. import tariffs, it said in the late Tuesday release.

Latest earningsOverall, the U.S. and Europe saw "solid local demand" in the three months to September, LVMH said, while Asia — with the exception of Japan — "saw a noticeable improvement in trends."

Organic growth for the third quarter came in at 1% year-on-year, marking a recovery from two consecutive quarters of declines. Year-to-date, the company's organic growth remained at 2% lower, however.

This is a breaking news story. Please refresh for updates.

Royal Mail has been hit with a £21 million fine after again failing to meet its annual delivery standards, with regulator Ofcom saying millions of letters across the UK arrived late.

The watchdog found that in the 2024–25 financial year, the postal operator delivered just 77% of first-class mail on time, below its 93% target, and 92.5% of second-class post, short of the 98.5% requirement.

It marks the third consecutive year Royal Mail has been penalised for missing its performance goals, making this the third-largest fine Ofcom has ever issued.

Ofcom said it had considered the impact of severe weather, including storms and flooding, but concluded the company still underperformed between April 2024 and March 2025. The fine was reduced from £30 million after Royal Mail admitted the breaches and agreed to settle.

Apple CEO Tim Cook poses on the red carpet at the 77th Primetime Emmy Awards in Los Angeles, California, U.S., September 14, 2025. REUTERS/David Swanson Purchase Licensing Rights, opens new tab

BEIJING, Oct 15 (Reuters) - Apple

(AAPL.O), opens new tab will boost investment in China and further step up cooperation there, Chief Executive Tim Cook told the industry minister during a meeting on Wednesday in the capital, Beijing, the ministry said in a summary of their remarks.

The comments come as the iPhone maker looks to sidestep U.S. tariffs on shipments from countries including its production hubs, China and India, by boosting already hefty investment in the United States to $600 billion over the next four years.

Sign up here.

China hopes Apple will continue to explore the Chinese market, Li Lecheng, who is also in charge of infotech, told Cook, adding that China would continue to foster a good business environment for foreign firms, including Apple.

The summary gave no details of the size of the projected investment. Apple did not immediately respond to a Reuters request for comment.

Cook, who is in China this week, visited Apple's store in Shanghai and met Chinese game developers and the designer of the popular Labubu dolls, he said in posts on China's X-like Weibo.

On Monday he said the iPhone Air would be available for pre-order in China after the ministry cleared the way for major telecom operators to support its eSIM functionality.

When Cook visited China in March, Apple unveiled plans for a new clean energy fund there worth 720 million yuan ($101 million).

($1=7.1258 Chinese yuan renminbi)

Reporting by Xiuhao Chen and Ryan Woo; Editing by Tom Hogue and Clarence Fernandez

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ -- To celebrate the upcoming launch of the exclusive Woolrich x Target collection, Target hosted a memorable event that perfectly captured the adventurous spirit of the collaboration.

Who: Olivia Palermo (Lifestyle and Fashion Influencer), Sean Kaufman (Actor), Lukas Gage (Actor), Nicky Campbell (Fashion Critic and Content Creator), Carla Rockmore (Fashion Designer), Greg Grippo (TV Personality), Sam Hine (GQ's Global Fashion Correspondent)

Olivia Palermo and Sean Kaufman celebrate the Woolrich x Target collaboration in NYC

Olivia Palermo debuts in the iconic buffalo check from the Woolrich x Target collection

‘The Summer I Turned Pretty’ star Sean Kaufman rocks Woolrich x Target at the NYC celebration event

Lukas Gage celebrates the Woolrich x Target collaboration in NYC

Nicky Campbell steps out in Woolrich x Target at the partnership celebration event in NYC

Samuel Hine celebrates the Woolrich x Target collaboration in NYC

Brigette Pheloung and Danielle Pheloung step out in Woolrich x Target at the partnership celebration event in NYC

What: To celebrate the limited-time only Woolrich x Target collection, Target hosted an event in NYC on Tuesday, October 14 at Triangle Lofts, 419 Lafayette St. The experience brought together the energy of the city and the adventure of the outdoors, giving guests an exclusive first look at pieces from the collaboration - designed to bring style to every kind of adventure.

Headline Entertainment: A live set by genre-bending DJ and co-host of the popular podcast How Long Gone, Them Jeans.
Curated Fashion Moments: Special guests including Sean Kaufman, Lukas Gage, Olivia Palermo, Lukas Gage, Sam Hine, Bridget and Danielle Pheloung, Carla Rockmore and Coco Chinelo were all styled in looks from the Woolrich x Target collection.
Immersive Guest Experiences: Guests walked through styling stations such as a Wooded Park emulating a cheerful city park and a Subway Station where guests watched Target stylists clad a live model in collection looks. A Peet's Coffee Bar served drinks from Peet's Coffee, which is a part of the Woolrich x Target assortment.
Content: Behind-the-scenes content of the event was captured by GQ's Global Fashion Correspondent, Samuel Hine.
When/Where: Tuesday, October 14, 2025 | 419 Lafayette Street, New York, NY

Background: This evening, Target celebrated the launch of the Woolrich x Target collection, a limited time only offering featuring over 100 items spanning men's and women's apparel, accessories, home, outdoor gear, and food and beverage – starting at just $2 and most items under $40. The assortment blends utility and style, merging classic craftsmanship with modern design trends. It features timeless archival pieces, like buffalo check jackets, alongside fresh additions such as a kayak, a completely new home line, and more. The Woolrich x Target collection will be available in most Target stores and online at Target.com starting Saturday, October 18.

About Target
Minneapolis-based Target Corporation (NYSE: TGT) serves guests at nearly 2,000 stores and at Target.com, with the purpose of helping all families discover the joy of everyday life. Since 1946, Target has given 5% of its profit to communities, which today equals millions of dollars a week. Additional company information can be found by visiting the corporate website and press center.

SOURCE Target Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Also from this source

ASML reports €7.5 billion total net sales and €2.1 billion net income in Q3 2025
Full-year 2025 expected total net sales growth of around 15% with gross margin around 52%

VELDHOVEN, the Netherlands, October 15, 2025 – Today, ASML Holding NV (ASML) has published its 2025 third-quarter results.

Q3 total net sales of €7.5 billion, gross margin of 51.6%, net income of €2.1 billionQuarterly net bookings in Q3 of €5.4 billion2 of which €3.6 billion is EUVASML expects Q4 2025 total net sales between €9.2 billion and €9.8 billion, and a gross margin between 51% and 53%ASML expects a full-year 2025 total net sales increase of around 15% relative to 2024, with a gross margin of around 52%ASML does not expect 2026 total net sales to be below 2025 (Figures in millions of euros unless otherwise indicated) Q2 2025
  Q3 2025 Total net sales 7,692
  7,516 ...of which Installed Base Management sales1 2,096
  1,962 New lithography systems sold (units) 67
  66 Used lithography systems sold (units) 9
  6 Net bookings2 5,541
  5,399 Gross profit 4,130
  3,880 Gross margin (%) 53.7
  51.6 Net income 2,290
  2,125 EPS (basic; in euros) 5.90
  5.49 End-quarter cash and cash equivalents and short-term investments 7,249
  5,128 (1) Installed Base Management sales equals our net service and field option sales.
(2) Net bookings include all system sales orders and inflation-related adjustments, for which written authorizations have been accepted.
Numbers have been rounded for readers' convenience. A complete summary of US GAAP Consolidated Statements of Operations is published on www.asml.com.

CEO statement and outlook
"Our third-quarter total net sales of €7.5 billion and gross margin of 51.6% were in line with our guidance, reflecting a good quarter for ASML.

"On the technology side, we see litho intensity continue to develop positively as EUV adoption gains momentum, including progress on High NA EUV. In line with our plans to support our customers in the 3D integration space, we shipped ASML’s first product serving Advanced Packaging, the TWINSCAN XT:260, an i-line scanner offering up to 4x productivity compared to existing solutions. Finally, our partnership with Mistral AI allows us to embed AI across our entire holistic portfolio, in order to increase the performance and productivity of our systems and the yield of our customers' processes.

"On the market side, we have seen continued positive momentum around investments in AI, and have also seen this extending to more customers, both in leading-edge Logic and advanced DRAM. On the other hand, we expect China customer demand, and therefore our China total net sales in 2026 to decline significantly compared to our very strong business there in 2024 and 2025.

"We do not expect 2026 total net sales to be below 2025. We will provide more details on our 2026 outlook in January.

"We expect fourth-quarter total net sales between €9.2 billion and €9.8 billion, with a gross margin between 51% and 53%. We expect R&D costs of around €1.2 billion and SG&A costs of around €320 million. For the full year 2025, we expect an increase of around 15% in total net sales and a gross margin of around 52%, with an expected very strong fourth quarter," said ASML President and Chief Executive Officer Christophe Fouquet.

  Update dividend and share buyback program
An interim dividend of €1.60 per ordinary share will be made payable on November 6, 2025.

In the third quarter, we purchased around €148 million worth of shares under the current 2022–2025 share buyback program.

As of September 28, 2025, ASML has acquired 9.0 million of shares under this program for a total consideration of €5.9 billion. ASML does not expect to complete the €12 billion share buyback program in full within the 2022–2025 timeframe. We intend to announce a new share buyback program in January 2026.

Details of the share buyback program as well as transactions pursuant thereto, and details of the dividend are published on ASML's website (www.asml.com/investors).

Media Relations contacts Investor Relations contacts Monique Mols +31 6 5284 4418 Jim Kavanagh +31 40 268 3938 Sarah de Crescenzo +1 925 899 8985 Pete Convertito +1 203 919 1714 Karen Lo +886 9 397 88635 Peter Cheang +886 3 659 6771  Quarterly video interview and investor call
With this press release, ASML is publishing a video interview in which CEO Christophe Fouquet and CFO Roger Dassen discuss the 2025 third quarter and outlook for 2025. This video and the video transcript can be viewed on www.asml.com shortly after the publication of this press release.

An investor call for both investors and the media will be hosted by CEO Christophe Fouquet and CFO Roger Dassen on October 15, 2025 at 15:00 Central European Time / 09:00 US Eastern Time. Details can be found on our website.

About ASML
ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity's toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,000 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.

US GAAP Reporting
ASML's primary accounting standard for quarterly earnings releases and annual reports is US GAAP, the accounting principles generally accepted in the United States of America. Quarterly summary US GAAP consolidated statements of operations, consolidated statements of cash flows and consolidated balance sheets are available on www.asml.com.

The consolidated balance sheets of ASML Holding N.V. as of September 28, 2025, the related consolidated statements of operations and consolidated statements of cash flows for the quarter and nine months ended September 28, 2025 as presented in this press release are unaudited.

Regulated information
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Forward Looking Statements

This document and related discussions contain statements that are forward-looking within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements with respect to plans, strategies, expected trends, including trends in the semiconductor industry and end markets, expected trends in product mix and geography, and business environment trends, expected growth in the semiconductor industry by 2030, statements with respect to AI including goals for use of AI in our portfolio and the expected impact of AI demand on our business, industry and results, statements with respect to EUV adoption, our expectation that lithography will remain at the heart of customer innovation, expected increase in critical lithography exposures, statements with respect to our product portfolio, our expectation that customer fundamentals remain strong, expected reduction in level of business uncertainty, expected demand, shipments, bookings, outlook of market segments, outlook and expected financial results including outlook and expected results for Q4 2025, including net sales, Installed Base Management sales, gross margin, R&D costs, SG&A costs, outlook and expected financial results for full year 2025, including expected full year 2025 total net sales and growth, gross margin, and estimated annualized effective tax rate and expected IBM sales, expectation of a very strong fourth quarter, and expectations with respect to EUV and DUV sales in 2026, expectations with respect to total 2026 net sales, statements made at our 2024 Investor Day, including modelled revenue and gross margin opportunity for 2030, our expectation to continue to return significant amounts of cash to shareholders through growing dividends and share buybacks, expectations with respect to our 2022-2025 share buyback program and plan to announce a new share buyback program in January 2026, and statements with respect to dividends, statements with respect to expected performance and capabilities of our systems and customer plans, statements with respect to our ESG strategy and commitments and other non-historical statements. You can generally identify these statements by the use of words like “may”, “expect”, “will”, “could”, “should”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “intend”, “continue”, “target”, “future”, “progress”, “goal”, “model”, “opportunity”, “commitment” and variations of these words or comparable words. These statements are not historical facts, but rather are based on current expectations, estimates, assumptions, plans and projections about our business and our future financial results and readers should not place undue reliance on them. Forward-looking statements do not guarantee future performance and involve a number of substantial known and unknown risks and uncertainties. These risks and uncertainties include, without limitation, risks relating to customer demand, semiconductor equipment industry capacity, worldwide demand for semiconductors and semiconductor manufacturing capacity, lithography tool utilization and semiconductor inventory levels, general trends and consumer confidence in the semiconductor industry, the impact of general economic conditions, including the impact of the current macroeconomic and geopolitical environment on the semiconductor industry, semiconductor market conditions, the ultimate impact of AI on our industry and business and semiconductor demand, the impact of inflation, interest rates, wars and geopolitical developments, the impact of pandemics, the performance of our systems, the success of technology advances and the pace of new product development and customer acceptance of and demand for new technologies and products, our production capacity and ability to adjust capacity to meet demand, supply chain capacity, timely availability of parts and components, raw materials, critical manufacturing equipment and qualified employees, our ability to produce systems to meet demand, the number and timing of systems ordered, shipped and recognized in revenue, risks relating to fluctuations in net bookings and our ability to convert bookings into sales, the risk of order cancellation, delays or push outs and restrictions on shipments of systems, including ordered systems, under export controls, risks relating to the trade environment, import/export and national security regulations and orders and their impact on us, including the impact of recent and future changes in export regulations and the impact of such regulations on our ability to obtain necessary licenses and to sell our systems and provide services to certain customers, the impact of the tariff announcements, exchange rate fluctuations, changes in tax rates, available liquidity and free cash flow and liquidity requirements, our ability to refinance our indebtedness, available cash and distributable reserves for, and other factors impacting, dividend payments and share repurchases, the number of shares that we repurchase under our share repurchase program, our ability to enforce patents and protect intellectual property rights and the outcome of intellectual property disputes and litigation, our ability to meet ESG goals and commitments and execute our ESG strategy, other factors that may impact ASML’s business or financial results, and other risks indicated in the risk factors included in ASML’s Annual Report on Form 20-F for the year ended December 31, 2024 and other filings with and submissions to the US Securities and Exchange Commission. These forward-looking statements are made only as of the date of this document. We undertake no obligation to update any forward-looking statements after the date of this report or to conform such statements to actual results or revised expectations, except as required by law.

Link to press release

Link to consolidated financial statements

-

UK solar installer training tour scheduled for November leverages significant growth in the number of systems with Tigo optimizers in the region.

MONTEVARCHI, Italy--(BUSINESS WIRE)--Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo”), a leading provider of intelligent solar and energy software solutions, today announced a three-stop training roadshow for UK solar installers. The golf-themed Tigo Hole-in-One Tour will feature hands-on technical education sessions in Glasgow, Rugby, and Bristol from November 3 to 6, 2025. The training roadshow follows the rapid growth in the number of solar installers in the region who choose Tigo for safe, monitored, and optimized solar with the Tigo TS4 Flex MLPE (Module Level Power Electronics) product family.

With the UK reaching over 2GW of operational solar capacity this year alone, the Kingdom has also become one of Tigo’s fastest-growing European markets. Driven in part by the Ofgem ECO4 program specifications for solar monitoring as well as innovations that deliver performance uplift, UK installers have adopted Tigo TS4 MLPE devices that deliver more energy through Reclaimed Energy with optimization, and remote monitoring via the Tigo Access Point (TAP) and Cloud Connect Advanced (CCA). Of the tens of thousands of monitored Tigo installations now deployed across the UK, more than 75% were installed in the last 5 years alone. In response to this strong momentum and an increase in the number of installers deploying Tigo products, the Company will increase the support, business, and training resources locally, starting with the Hole-in-One Tour.

“We have relied on Tigo optimizers for years because of how well they perform in UK conditions, which often include suboptimal roof orientations for modules, and not infrequent cloud-related system shading,” said Anthony Dixey, CEO at AWD Electrical Ltd T/A Economy Energy Group. “These new training sessions will be a great opportunity to do a deep dive with the Tigo EI Residential Solution and connect directly with the Tigo team. It’s good to see a solar equipment manufacturing company investing in installers and making hands-on learning accessible.”

Each of the three training sessions will feature hands-on product training, system design guidance, and direct access to Tigo experts. Installers will receive practical experience with the Tigo EI Residential Solution, an all-in-one system that integrates inverter, battery, and optimization technologies for simplified installation, intelligent energy management, and reliable backup power for multiple household loads. The training will also cover the Tigo TS4-A-O MLPE models, which deliver advanced module-level monitoring, enhanced energy harvesting through optimization, and increased power and current to keep pace with the increase in high-current solar modules deployed by installers to offer customers the most energy production per available rooftop space. Tigo TS4-A-O devices support solar modules up to 700W and are rated for a maximum short-circuit current of 20A and a maximum input voltage of 80V per module. The TS4-A products are fully backward-compatible with other Tigo TS4 products and are certified compatible with hundreds of inverter models.

“With hundreds of thousands of monitoring-enabled Tigo MLPE devices installed across the region, it was time to ensure that our growing list of installer partners has the training and support to keep making them successful with a complete Tigo optimized Energy Storage System," said Mirko Bindi, Senior VP Sales EMEA & MD Europe at Tigo Energy. “Installers are at the center of our growth around the world, and our UK training tour reflects another part of our ongoing investment in training, personnel, and support for the installer community across the UK.”

Building on strong engagement from UK installers at the Greentech trade show in September, the Hole-in-One Tour also supports the Tigo Green Glove installer success program, which provides advanced technical training, certification, and ongoing support for Tigo installation partners. Installers can register for one of the training sessions in Glasgow, Rugby, or Bristol from November 3 to 6, 2025, here.

About Tigo Energy

Founded in 2007, Tigo Energy, Inc. (Nasdaq: TYGO) is a worldwide leader in the development and provider of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.

More News From Tigo

Back to Newsroom

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained impact on patient outcomesMore than 40 abstracts across MG, CIDP, MMN, and IIM highlight depth of clinical evidence and ongoing commitment to rare neuromuscular disease communities October 15, 2025, 7:00 AM CEST

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidate empasiprubart at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco from October 29-November 1, 2025.

“We’re proud to have a robust presence at this year’s AANEM Annual Meeting and MGFA Scientific Session, where we are sharing pivotal data and meaningful evidence across a broad spectrum of serious neuromuscular diseases, including MG, CIDP, MMN and IIM,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer, argenx. “The breadth of studies reflect the strength and momentum of our clinical development programs, from the continued expansion of VYVGART into new patient populations, to our fast-approaching growth opportunity with empasiprubart. These presentations also underscore our commitment to generating evidence that propels innovation and positively impacts people living with these debilitating diseases.”

Abstracts at AANEM and MGFA will highlight real-world and clinical data demonstrating the potential of argenx’s innovative therapies to help more people living with autoimmune and neuromuscular diseases.

Advancing VYVGART in Treating Additional gMG Patient Populations

Results from the Phase 3 ADAPT SERON study evaluating VYVGART for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody negative (AChR-Ab seronegative) show clinically meaningful improvements in disease activity across all three subtypes (triple negative, MuSK, and LRP4-Ab seropositive).ADAPT Jr interim results assess age-appropriate dosing, safety, and clinical effect of VYVGART in juvenile gMG. Driving CIDP Innovation with VYVGART Hytrulo and Empasiprubart

VYVGART Hytrulo CIDP data highlight functional improvement, long-term safety, and real-world characteristics of patients, underscoring the need for early treatment with effective and well-tolerated therapies.Two Phase 3 study designs for empasiprubart in CIDP – EMVIGORATE and EMNERGIZE – demonstrate argenx’s commitment to advancing innovative therapies and transforming outcomes for patients. Progressing Development of Empasiprubart in MMN

Phase 2 ARDA study highlights clinical efficacy and safety data of empasiprubart in treated patients with multifocal motor neuropathy (MMN). Phase 3 study design – EMPASSION – will evaluate the efficacy and safety of empasiprubart versus IVIg in adult patients with MMN.Real-world data characterize MMN disease burden, management, and quality of life, reinforcing the need for therapeutic approaches that reduce the use of burdensome treatments and improve functional outcomes. Details for oral and poster presentations at AANEM and MGFA are as follows:

Oral Presentations at MGFATitlePresentationGeneralized Myasthenia Gravis (gMG)Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia GravisPresenter: James F. Howard

MGFA
Oral Presentation​
#101
Session B: Therapeutics and Clinical Trials
Wednesday, October 29
10:40 a.m. PTResults From the ADAPT Jr Study Investigating Intravenous Efgartigimod in Juvenile Generalized Myasthenia GravisPresenter: Abigail N. Schwaede

MGFA
Oral Presentation​
#113
Session B: Therapeutics and Clinical Trials
Wednesday, October 29
10:20 a.m. PTReduction in Oral Glucocorticoid Use at 18 Months Following Efgartigimod Initiation Based on a United States Claims DatabasePresenter: Neelam Goyal

MGFA
Oral Presentation
#100
Session C: Patient Care, Hot Topics, Retrospective/Post-hoc Studies
Wednesday, October 29
1:16 p.m. PT Poster Presentations* at AANEM and MGFATitlePresentationGeneralized Myasthenia Gravis (gMG)Sustained Clinical Efficacy and Long-term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of Adapt NXTAANEM
Poster #260​
Poster Sessions I & IIClinical Development Program for Efgartigimod in Juvenile Generalized Myasthenia GravisAANEM
Poster #257​
Poster Sessions I & IICost and Use of Medical Devices in Incident Early-Onset Myasthenia Gravis Patients in FranceAANEM
Poster #161​
Poster Sessions I & IIIDisability Progression and Associated Costs in Incident Early-onset Myasthenia Gravis Patients in France: A Longitudinal Cohort StudyAANEM
Poster #162​
Poster Sessions I & IIILong-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants with Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ StudyAANEM
Poster #12
Poster Sessions I & IIIHigh Cardiovascular Disease Burden Among Patients with Myasthenia Gravis in USMGFA
Poster #38Evaluation of Cardiovascular Comorbidity Burden in Patients with Generalized Myasthenia Gravis Treated with EfgartigimodMGFA
Poster #68​Impact of Long-Term Intravenous Efgartigimod on Quality of Life, Disease Severity, and Safety in Participants with Generalized Myasthenia Gravis during ADAPT NXTMGFA
Poster #76 ​Design of a Phase 3 Randomized, Double Blinded, Placebo-Controlled Study Evaluating Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults with Ocular Myasthenia GravisMGFA
Poster #14 ​Myasthenia Gravis Events in a Retrospective United States Claims Database StudyAANEM
Poster #258
Poster Sessions I & IIDesign of a Phase 4, Open-Label, Single-Group Study to Evaluate Clinical Outcomes of Efgartigimod PH20 Sc in Adult Participants with New-Onset Generalized Myasthenia GravisAANEM
Poster #232
Poster Sessions I & IIComparative Benefits of Immunomodulatory Therapies for Generalized Myasthenia Gravis​MGFA
Poster #72Patient Characteristics, Dosing Patterns, and Outcomes Associated with Intravenous and Subcutaneous Efgartigimod Among Patients with Generalized Myasthenia Gravis in Clinical Practice​MGFA
Poster #70Drivers of Mortality in Patients with Myasthenia Gravis in the United States National Veterans Affairs Health Care Network and Medicare DatabasesMGFA
Poster #71Diagnosis Journey, Treatment, and Management of Patients with Ocular Myasthenia Gravis: Insights from a U.S. Patient PanelMGFA
Poster #63Disease Burden, Impact on Daily Functioning, and Psychological Well-being in Patients with Ocular Myasthenia Gravis: Insights from a U.S. Patient Panel​MGFA
Poster #62Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Empasiprubart Versus Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: EMVIGORATE Phase 3 Study DesignAANEM
Poster #249
Poster Sessions I & IIIEmpasiprubart Versus Placebo in Chronic Inflammatory Demyelinating Polyneuropathy: EMNERGIZE Phase 3 Study DesignAANEM
Poster #251
Poster Sessions I & IIIImpact of Subcutaneous Efgartigimod PH20 on Autoimmune Biomarkers in the ADHERE Trial: Exploratory AnalysisAANEM
Poster #325
Poster Sessions I & IIITreatment Impact of Efgartigimod PH20 SC on I-RODS Daily Activity Assessment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Post Hoc Analysis of the Registrational ADHERE StudyAANEM
Poster #246
Poster Sessions I & IIAutoantibody Signatures in Chronic Inflammatory Demyelinating Polyneuropathy: Insights on Glycolipid Reactivity From the ADHERE TrialAANEM
Poster #248
Poster Sessions I & IITransition From Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants with Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in ProgressAANEM
Poster #250
Poster Sessions I & IIADHERE+ Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating PolyneuropathyAANEM
Poster #217
Poster Sessions I & IIICharacteristics of Patients with Chronic Inflammatory Demyelinating Polyneuropathy Initiating Subcutaneous Efgartigimod in the United StatesAANEM
Poster #141
Poster Sessions I & IIIGlucocorticoid Exposure and the Risk of Serious Infections in CIDPAANEM
Poster #160
Poster Sessions I & IIPre-existing Conditions Among Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy in the United StatesAANEM
Poster #150
Poster Sessions I & IIThe Diagnostic Experience of Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Results of a Real-World Survey in the United StatesAANEM
Poster #255
Poster Sessions I & IIIPhysician and Patient Satisfaction with Chronic Inflammatory Demyelinating Polyneuropathy Treatment: Results of a Real-World Survey in the United StatesAANEM
Poster #139
Poster Sessions I & IIIReal-World Characteristics of Patients Initiating Efgartigimod Subcutaneous in the United States: Insights From a Patient Support ProgramAANEM
Poster #140
Poster Sessions I & IIMultifocal Motor Neuropathy (MMN)Safety and Efficacy Data From the Phase 2 ARDA Study of Empasiprubart in Multifocal Motor NeuropathyAANEM
Poster #215
Poster Sessions I & IIEmpasiprubart in Multifocal Motor Neuropathy: Exploratory Analyses of the Phase 2 ARDA StudyAANEM
Poster #239
Poster Sessions I & IIIBurden of Disease in Multifocal Motor Neuropathy: A Global Quantitative Survey of PatientsAANEM
Poster #242
Poster Sessions I & IIIManagement of Patients with Multifocal Motor Neuropathy: A Global Quantitative Survey of NeurologistsAANEM
Poster #243
Poster Sessions I & IIIEmpasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSIONAANEM
Poster #244
Poster Sessions I & IIIBaseline Characteristics of the First 200 Study Participants with Multifocal Motor Neuropathy in the Immersion StudyAANEM
Poster #326
Poster Sessions I & IIIA Real-World Retrospective Cohort Study Characterizing Patients with MMN in the United StatesAANEMPoster #327

Poster Sessions I & III

Idiopathic Inflammatory Myopathy (IIM)Efficacy and Safety of Subcutaneous Efgartigimod in Adult Participants with Active Idiopathic Inflammatory Myopathy: Phase 2 Results From the ALKIVIA StudyAANEM
Poster #218
Poster Sessions I & IIMultiple Disease AreasSafety of Intravenous and Subcutaneous Efgartigimod Reported From Multiple Global Clinical Trials in Immunoglobulin G-Mediated Autoimmune DiseasesAANEM
Presentation #245
Poster Sessions I & IIInvestigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled SyringeAANEM
Poster #256
Poster Sessions I & IIIFcRn Blocker Efgartigimod: Unique Fc Fragment Allowing IgG Reduction Without Reducing Albumin or Increasing CholesterolAANEM
Poster #400​
Poster Sessions I & IICOVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 AANEM
Poster #259
Poster Sessions I & III *Session Times:

Session I: Thursday, October 30, 6:15-6:45 p.m. PTSession II: Friday, October 31, 9:30-10:00 a.m. PTSession III: Friday, October 31, 2:45-3:15 p.m. PT More information on the data presented at the 2025 AANEM Annual Meeting and MGFA Scientific Session can be found here.

Important Safety Information 

What is VYVGART® (efgartigimod alfa-fcab)? 
VYVGART is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

  IMPORTANT SAFETY INFORMATION 
Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. VYVGART can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

  VYVGART may cause serious side effects, including: 

Infection. VYVGART may increase the risk of infection. The most common infections were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. Allergic Reactions (hypersensitivity reactions). VYVGART can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with VYVGART.  Infusion-Related Reactions. VYVGART can cause infusion-related reactions. The most frequent symptoms and signs reported with VYVGART were high blood pressure, chills, shivering, and chest, abdominal, and back pain.    Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

  Before taking VYVGART, tell your doctor if you: 

take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have received or are scheduled to receive a vaccine (immunization), or have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.  What are the common side effects of VYVGART? 
The most common side effects of VYVGART are respiratory tract infection, headache, and urinary tract infection.

These are not all the possible side effects of VYVGART. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088. 

Please see the full Prescribing Information for VYVGART and talk to your doctor. 

Important Safety Information 

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with:

generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.chronic inflammatory demyelinating polyneuropathy (CIDP). It is not known if VYVGART HYTRULO is safe and effective in children.

IMPORTANT SAFETY INFORMATION 
Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

  Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

have an infection or fever.have recently received or are scheduled to receive any vaccinations.have any history of allergic reactions.have kidney (renal) problems.are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby. Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection: fever, chills, frequent and painful urination, cough, pain and blockage or nasal passages, wheezing, shortness, sore throat, excess phlegm, nasal discharge.Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: rash, swelling of the face, lips, throat, or tongue, shortness of breath, hives, trouble breathing, low blood pressure, fainting.Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction: high blood pressure, chills, shivering, chest, stomach, or back pain. The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor. 

About VYVGART and VYVGART Hytrulo
VYVGART® (efgartigimod alfa fcab) is a first-in-class human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. VYVGART® Hytrulo is a subcutaneous combination of efgartigimod alfa (VYVGART) and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. VYVGART is approved for generalized myasthenia gravis (gMG) and immune thrombocytopenia (Japan only). VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo may be marketed under different proprietary names in other regions.

About Empasiprubart
Empasiprubart (ARGX-117) is a novel humanized monoclonal antibody that binds C2 and blocks activation of both the classical and lectin pathways of the complement cascade. By blocking complement activity upstream of C3 and C5, empasiprubart has the potential to reduce tissue inflammation and cellular damage, representing a broad pipeline opportunity across multiple severe autoimmune indications. In addition to multifocal motor neuropathy, argenx is evaluating empasiprubart in delayed graft function following kidney transplant, and chronic inflammatory demyelinating polyneuropathy (CIDP).

About Generalized Myasthenia Gravis (gMG)
Generalized myasthenia gravis (gMG) is a rare and chronic autoimmune disease where IgG autoantibodies disrupt communication between nerves and muscles, causing debilitating and potentially life-threatening muscle weakness. Approximately 85% of people with MG progress to gMG within 24 months¹, where muscles throughout the body may be affected. Patients with confirmed AChR antibodies account for approximately 85% of the total gMG population.

About AChR-Ab seronegative gMG
gMG is a rare, chronic, neuromuscular autoimmune disease caused by pathogenic IgGs targeting the neuromuscular junction (NMJ), resulting in impaired neuromuscular transmission and debilitating and potentially life-threatening muscle weakness and chronic fatigue. Approx. 80% of patients with gMG have detectable antibodies against the AChR in sera, and these patients are diagnosed as AChR-Ab seropositive gMG. Approximately 20% of patients with gMG do not have detectable serum antibodies directed against AChR and are referred to as AChR-Ab seronegative gMG. These patients may have detectable autoantibodies targeting other NMJ proteins, such as muscle-specific tyrosine kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4), or others. Anti-MuSK antibodies are detected in approximately 1-10% of patients with gMG, while anti-LRP4 antibodies are detected in approximately 1-5% of patients with gMG. About 10% of patients do not have any detectable autoantibodies against AChR, MuSK or LRP4. These triple seronegative patients have historically been excluded from studies and have a higher disease burden and unmet medical need compared to patients with detectable autoantibodies. Currently, there are no approved treatments available for patients with anti-LRP4 antibodies or for triple seronegative patients.

About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP is a rare and serious autoimmune disease of the peripheral nervous system. There is increasing evidence that IgG antibodies play a key role in the damage to the peripheral nerves. People with CIDP experience fatigue, muscle weakness and a loss of feeling in their arms and legs that can worsen over time or may come and go. These symptoms can significantly impair a person's ability to function in their daily lives. Without treatment, one-third of people living with CIDP will need a wheelchair.

About Multifocal Motor Neuropathy
Multifocal motor neuropathy (MMN) is a rare, severe, chronic autoimmune disease of the peripheral nervous system. The disease is characterized by slowly progressive, asymmetric muscle weakness mainly of the hands, forearms and lower legs. MMN is often associated with the presence of anti-GM1 IgM autoantibodies, leading to activation of the classical complement pathway, driving subsequent axon damage. High-dose IVIg is the only approved treatment for MMN and patients typically experience disease progression despite therapy, indicating an unmet need for efficacious and better tolerated therapeutic options.

About Idiopathic Inflammatory Myopathies
Idiopathic inflammatory myopathies (myositis) are a rare group of autoimmune diseases that can be muscle specific or affect multiple organs including the skin, joints, lungs, gastrointestinal tract and heart. Myositis can be very severe and disabling and have a material impact on quality of life. Initially, myositis was classified as either DM or polymyositis, but as the underlying pathophysiology of myositis has become better understood, including through the identification of characteristic autoantibodies, new polymyositis subtypes have emerged. Two of these subtypes are IMNM and ASyS. Proximal muscle weakness is a unifying feature of each subtype. IMNM is characterized by skeletal muscle weakness due to muscle cell necrosis. ASyS is characterized by muscle inflammation, inflammatory arthritis, interstitial lung disease, thickening and cracking of the hands (“mechanic’s hands”) and Raynaud’s phenomenon. DM is characterized by muscle inflammation and degeneration and skin abnormalities, including heliotrope rash, Gottron’s papules, erythematous, calcinosis and edema.

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

References
1 Behin et al. New Pathways and Therapeutics Targets in Autoimmune Myasthenia Gravis. J Neuromusc Dis 5. 2018. 265-277

Media:
Colin McBean
[email protected]

Investors:
Alexandra Roy
[email protected]

FORWARD LOOKING STATEMENTS
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “aim,” “believe,” “can,” “continue,” “evaluate,” “may,” “progress,” and “will” and include statements argenx makes concerning the ADAPT SERON results and interim ADAPT Jr data, including VYVGART’s potential to treat a broad set of MG patients; the continued expansion of VYVGART into new patient populations; its potential growth opportunity with empasiprubart, including the timing thereof; its commitment to generating evidence through its various studies and positively impact patients living with serious neuromuscular diseases; the data for VYVGART, VYVGART Hytrulo and empasiprubart that will be presented at the upcoming AANEM Annual Meeting and MGFA Scientific Session, including the agenda for such meetings; its commitment to advancing innovative therapies and transforming outcomes for patients, including with the EMVIGORATE and EMNERGIZE studies; its goal of (i) advancing VYVGART in treating additional gMG patient populations, (ii) driving CIDP innovation with VYVGART Hytrulo and empasiprubart and (iii) progressing the development of empasiprubart in MMN; its evaluation of emprasiprubart in delayed graft function following kidney transplant and chronic CIDP; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

ASML logo is seen in this illustration taken February 16, 2025. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniesASML expects significant fall in China demand next yearAnalysts disappointed by ASML's flat sales guidance for 2026ASML's Q3 net bookings slightly exceed analyst expectationsOct 15 (Reuters) - ASML

(ASML.AS), opens new tab, the world's biggest supplier of computer chip-making equipment, on Wednesday repeated it expects to benefit from booming investments in AI, but warned that it expected a significant fall in demand from China next year.

Analysts said the lukewarm guidance, which said sales will be flat or better in 2026, may be upgraded in January.

Sign up here.

"It could have been a stronger message," Michael Roeg of Degroof Petercam said.

Net bookings, the most closely watched figure in the industry, were 5.40 billion euros ($6.27 billion) in the third quarter of 2025, versus analysts' consensus estimate of 5.36 billion euros, according to researcher Visible Alpha.

The results came after a flurry of mega-deals between AI firms and chipmakers in September and October, all of which will mean more demand for chips, which make up around half of the cost of data centres.

CEO Christophe Fouquet said ASML, Europe's largest tech firm by market capitalization, is seeing "continued positive momentum around investments in AI," and that it was extending to more of its customers both in advanced logic chips such as those used in smartphones and AI datacenters, and advanced memory chips also needed for AI.

ASML's lithography tools, which are essential for making the circuitry of chips, are sold to TSMC of Taiwan

(2330.TW), opens new tab, which manufactures most AI chips for Nvidia and other logic firms such as SMIC

(0981.HK), opens new tab of China and Intel

(INTC.O), opens new tab of the U.S. It also serves memory chip makers Samsung

(005930.KS), opens new tab SK Hynix

(000660.KS), opens new tab, and Micron

(MU.O), opens new tab, among others.

Weak Chinese demand came as a surprise after it made up nearly a third of new ASML tool sales through the first nine months of 2025.

"We expect China customer demand, and therefore our China total net sales in 2026 to decline significantly," Fouquet said.

The company reported third-quarter net income of 2.12 billion euros in line with the 2.11 billion euros analysts expected, according to LSEG IBES data.

($1 = 0.8607 euros)

Reporting by Toby Sterling in Amsterdam, Nathan Vifflin in Gdansk; Editing by Matt Scuffham and Kim Coghill

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ORCL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

ASML reported €5.4 billion ($6.3 billion) in bookings for the third quarter, beating analyst expectations. The demand for its chip-making machines was fueled by investment into artificial intelligence infrastructure.

LVMH sales unexpectedly returned to growth in the third quarter as shoppers splurged on Moët & Chandon Champagne and Dior perfumes. The world's largest luxury group, led by billionaire Bernard Arnault, has endured an extended pullback, particularly in China, which had long been a driver of growth.

Vancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - Thor Explorations Ltd. (TSXV: THX) (AIM: THX) ("Thor Explorations" or the "Company") is pleased to provide its third quarter 2025 interim operational update for the Segilola Gold mine, located in Nigeria ("Segilola"), and for the Company's mineral exploration properties located in Nigeria, Senegal, and Côte d'Ivoire, for the three months to September 30, 2025 (the "Quarter" or "Q3").

SummaryCompaniesItaly has retained gold despite crises, mounting debtBank of Italy holds 2,452 tons, World Gold Council saysCountry has world's third largest national bullion reservesItaly's ties to gold rooted in historyROME, Oct 15 (Reuters) - Italy, whose sovereign assets from bonds to banks have so often been the subject of market crises in recent years, is currently enjoying a windfall as the central bank's vast gold reserves track record-high prices.

The country's bullion stockpile reflects decades of determined safeguarding after it rebuilt reserves plundered by the Nazis in the 1940s, and a stance that has seen it resist calls to sell through repeated crises and as its national debt soared.

Sign up here.

The Bank of Italy now sits on the world's third-largest national gold stockpile, behind only the U.S. and Germany. Its 2,452 metric tons of gold are worth an estimated $300 billion at current prices, roughly 13% of 2024 national output, Reuters calculations show.

Top 10 central bank gold holdings as of March 2025WARTIME SEIZURES SHAPE PEACETIME POLICYItaly's love affair with bullion goes back millennia, with the Etruscans mastering the technique of fusing gold beads well before ancient Rome. Under Julius Caesar, the aureus gold coin became the monetary cornerstone of the Roman Empire, and centuries later, the fiorino became as influential in medieval Europe as the dollar is today.

The country's more recent gold policy was shaped by its wartime experience, when Nazi forces aided by Italy's own fascist regime seized 120 tons of its reserves. By the war's end, these had dwindled to around 20 tons.

During its postwar "economic miracle", Italy became an export-driven economy and saw a surge in foreign currency inflows, notably U.S. dollars. Some of these, according to the Bank of Italy's website, were converted into gold.

Its holdings had climbed to 1,400 tons by 1960, including three-quarters of the seized bullion which it was able to recover in 1958.

Largest official sector gold holdersTHE FAMILY SILVERWAREThe oil shocks of the 1970s ushered in further global uncertainty, which in Italy meant social unrest and frequent government changes seen as risky by investors.

"The extreme monetary instability led the central banks of Western countries to buy gold, the ultimate symbol of financial solidity," Stefano Caselli, dean of the SDA Bocconi School of Management in Milan, told Reuters.

To offset budget holes left by capital flight, Rome used 41,300 ingots from its gold reserves as collateral for a $2 billion loan from Germany's Bundesbank in 1976.

But unlike Britain or Spain, Italy has refused to sell off gold during financial downturns, retaining its reserves even through the 2008 debt crisis.

"Gold is like the family silverware, it's like grandpa's precious watch, it's the last resort in times of crisis, any crisis that undermines international confidence in the country," Salvatore Rossi, former deputy governor of the Bank of Italy, wrote in his 2018 book 'Oro' (Gold).

DECISION FOR A MODERN ERAWith gold still viewed as a safeguard of last resort by many Western nations, central banks worldwide are again stockpiling amid a reshaping of the global order.

"That historical decision of the Bank of Italy feels strikingly modern," said Caselli. "Because we are back there again."

Top net official sector buyers of gold so far in 2025The Bank of Italy currently holds approximately 871,713 gold coins weighing some 4.1 tons in its vaults, dubbed the 'sacristy' after the room in a church where sacred items are kept.

Gold accounted for nearly 75% of Italy's official reserves at the end of last year, a significantly higher ratio than the 66.5% of the euro zone, according to World Gold Council data.

Around 1,100 tons are stored in the vault beneath the Bank of Italy's headquarters at Palazzo Koch, a short walk from the Colosseum. A similar portion is held in the U.S., while smaller amounts are kept in Britain and Switzerland.

Italy also remains one of the world's top exporters of gold jewellery, with production concentrated in Alessandria, Arezzo, and Vicenza. Luxury brands like Bulgari, Buccellati and Damiani enjoy global acclaim.

THE HOTTEST ASSETCalls to sell gold to reduce Italy's public debt, now over 3 trillion euros ($3.49 trillion) and seen at 137.4% of GDP next year, continue to surface but have not yet succeeded.

"Selling even half of the gold holding would not solve Italy's debt problem anyway," said Giacomo Chiorino, head of market analysis at Banca Patrimoni Sella & C.

Some argue that selling ingots could unlock funding for essential public services to benefit citizens instead of sitting idly in vaults.

Nonetheless, the Bank of Italy shows no intention of selling. It had no comment on its gold policy for this article.

"At a time when the world is being redrawn, market prices have reached unprecedented multiples and (digital assets such as) stablecoins and cryptocurrency are gaining ground, central banks currently hold the hottest asset," Bocconi's Caselli said. "They are right not to sell."

($1 = 0.8607 euros)

Reporting by Giselda Vagnoni; Editing by Jan Harvey

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Rakuten logo is seen in this illustration taken, February 11, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

SummaryCompaniesIPO considerations in early stages -sourceOther options include a stake sale -sourceSoftBank is preparing to list PayPay in USMizuho bought a 15% stake in Rakuten card business for $1.1 billionTOKYO, Oct 15 (Reuters) - Japanese e-commerce and finance heavyweight Rakuten

(4755.T), opens new tab is weighing an initial public offering in the United States of its credit card business, according to two sources familiar with the matter.

Rakuten began considering a potential U.S. listing of one of Japan's largest credit card businesses last month, the sources said. The considerations are in the early stages, with other potential options including a stake sale to a strategic buyer, one of the sources said.

Sign up here.

One trigger for considering a U.S. IPO of Rakuten Card was rival SoftBank's

(9984.T), opens new tab plans to list app pay operator PayPay in the U.S., the source said. The sources declined to be named as the information is not public.

The company's considerations of a U.S. IPO had not been reported previously.

Rakuten did not respond to requests for comment.

Mizuho Financial Group

(8411.T), opens new tab acquired a 15% stake in Rakuten Card for 165 billion yen ($1.1 billion) last year, valuing the business at more than 1 trillion yen, or $7 billion, with the two launching joint credit cards.

For PayPay, institutional investors see a baseline valuation of 2 trillion yen, but expect the valuation could exceed 3 trillion yen in the IPO that could take place as early as December, Reuters reported this week.

CARDS CENTRAL TO RAKUTEN'S BUSINESSRakuten, which is led by founder and CEO Hiroshi Mikitani, shook up Japan's finance sector by simplifying the process for applying for credit cards and making them available to a wider range of consumers.

Credit cards are an important part of a web of Rakuten businesses spanning online shopping, banking, travel and other services, with customers accruing loyalty reward points by making payments.

Rakuten listed Rakuten Bank

(5838.T), opens new tab in Tokyo two years ago as the group reeled from heavy losses due to launching a mobile network.

Rakuten also announced plans to list Rakuten Securities, but Mizuho injected funding by taking stakes in the brokerage and card businesses.

Rakuten Card has issued more than 30 million credit cards in Japan. Non-GAAP operating profit at the business grew 20% to 62 billion yen last year but fell 4.5% in the April-June quarter of this year compared to the same period a year earlier due to higher costs.

Rakuten Card aims to expand profit to 100 billion yen over the medium term and is looking to expand its business with corporate customers, its CEO Koichi Nakamura said in March.

The IPO considerations come as companies around the world are looking to list in the U.S. as they seek higher valuations.

The U.S. IPO market has had its busiest quarter since the fourth quarter of 2021, with companies raising $24 billion through first-time share sales in the third quarter, according to Dealogic.

($1 = 152.0900 yen)

Reporting by Miho Uranaka and Sam Nussey; Editing by Jamie Freed

Our Standards: The Thomson Reuters Trust Principles., opens new tab